-
公开(公告)号：US20240287196A1
公开(公告)日：2024-08-29
申请号：US18613372
申请日：2024-03-22
Applicant: Acceleron Pharma Inc.
Inventor： Ravindra Kumar , Roselyne Castonguay , Dianne Sako , Jonathan Belk , Nathan J. Sharkey
CPC classification number: C07K16/2863 , A61P3/06 , A61K2039/505 , C07K2317/34 , C07K2317/92
Abstract: This disclosure provides ALK7-binding proteins such as anti-ALK7 antibodies, and compositions and methods for making the ALK7-binding proteins. In certain embodiments the ALK7-binding proteins inhibit or antagonize ALK7 activity. In addition, the disclosure provides compositions and methods for diagnosing and treating overweight, obesity, diabetes, overweight, obesity, type 2 diabetes, and their associated conditions; metabolic disorders, and other diseases or conditions that can be treated, prevented, or ameliorated by targeting ALK7.
-
公开(公告)号：US11059894B2
公开(公告)日：2021-07-13
申请号：US16696411
申请日：2019-11-26
Applicant: Acceleron Pharma Inc. , Adimab, LLC
Inventor： John Knopf , Jonathan Belk , Nathan J. Sharkey , Ravindra Kumar , Asya Grinberg , Dianne Sako , Roselyne Castonguay , Yossi Dagon
Abstract: This disclosure provides ALK7-binding proteins such as anti-ALK7 antibodies, and compositions and methods for making the ALK7-binding proteins. In certain embodiments the ALK7-binding proteins inhibit, or antagonize ALK7 activity. In addition, the disclosure provides compositions and methods for diagnosing and treating overweight, obesity, diabetes, overweight, obesity, type 2 diabetes, and their associated conditions; metabolic disorders, and other diseases or conditions that can be treated, prevented or ameliorated by targeting ALK7.
-
公开(公告)号：US20200087406A1
公开(公告)日：2020-03-19
申请号：US16696411
申请日：2019-11-26
Applicant: Acceleron Pharma Inc. , Adimab, LLC
Inventor： John Knopf , Jonathan Belk , Nathan J. Sharkey , Ravindra Kumar , Asya Grinberg , Dianne Sako , Roselyne Castonguay , Yossi Dagon
Abstract: This disclosure provides ALK7-binding proteins such as anti-ALK7 antibodies, and compositions and methods for making the ALK7-binding proteins. In certain embodiments the ALK7-binding proteins inhibit, or antagonize ALK7 activity. In addition, the disclosure provides compositions and methods for diagnosing and treating overweight, obesity, diabetes, overweight, obesity, type 2 diabetes, and their associated conditions; metabolic disorders, and other diseases or conditions that can be treated, prevented or ameliorated by targeting ALK7.
-
公开(公告)号：US12042524B2
公开(公告)日：2024-07-23
申请号：US17231981
申请日：2021-04-15
Applicant: Acceleron Pharma Inc.
Inventor： Ravindra Kumar , Jonathan Belk , Asya Grinberg , Dianne Sako , Roselyne Castonguay
CPC classification number: A61K38/02 , A61K38/16 , C07K14/001 , C07K14/47 , C07K16/2863 , A61K38/00 , C07K5/00 , C07K2317/21 , C07K2317/34 , C07K2317/55 , C07K2317/76 , C07K2317/92
Abstract: This disclosure provides ActRII-binding proteins such as anti-ActRIIA and anti-ActRIIB antibodies, and compositions and methods for making the ActRII-binding proteins. In certain aspects the ActRII-binding proteins inhibit, or antagonize ActRII activity. In addition, the disclosure provides compositions and methods for diagnosing and treating diseases and conditions associated musle wasting; a fibrotic condition; an inflammatory, cardiovascular, pulmonary, musculoskeletal, neurologic, ocular, skeletal, autoimmune, or metabolic disease or condition; wound healing; and cancer, and other ActRII-mediated diseases and conditions.
-
公开(公告)号：US11981738B2
公开(公告)日：2024-05-14
申请号：US16757959
申请日：2018-10-25
Applicant: Acceleron Pharma Inc. , Adimab, LLC
Inventor： Ravindra Kumar , Roselyne Castonguay , Dianne Sako , Jonathan Belk , Nathan J. Sharkey
IPC: A61K39/395 , A61P3/06 , C07K16/28 , A61K39/00
CPC classification number: C07K16/2863 , A61P3/06 , A61K2039/505 , C07K2317/34 , C07K2317/92
Abstract: The disclosure provides ALK7-binding proteins such as anti-ALK7 antibodies, and compositions and methods for making the ALK7-binding proteins. In certain embodiments, the ALK7-binding proteins inhibit, or antagonize ALK7 activity. In addition, the disclosure provides compositions and methods for diagnosing and treating overweight, obesity, diabetes, obesity, type 2 diabetes, and their associated conditions, metabolic disorders, and other diseases or conditions that can be treated by targeting ALK7.
-
Patent Agency Ranking
公开(公告)号：US20220242956A1
公开(公告)日：2022-08-04
申请号：US17615474
申请日：2020-05-29
Applicant: Acceleron Pharma Inc.
Inventor： Ravindra Kumar , Jonathan Belk , Asya Grinberg , Dianne Sako , Roselyne Castonguay
Abstract: This disclosure provides ActRII-binding proteins such as anti-ActRIIA and anti-ActRIIB antibodies, and compositions and methods for making the ActRII-binding proteins. In certain embodiments, the ActRII-binding proteins inhibit, or antagonize ActRII activity. In addition, the disclosure provides compositions and methods for diagnosing and treating diseases and conditions associated with muscle wasting; a fibrotic condition; an inflammatory, cardiovascular, pulmonary, musculoskeletal, neurologic, ocular, skeletal, autoimmune, or metabolic disease or condition; wound healing; and cancer, and other ActRII-mediated diseases and conditions.
-
公开(公告)号：US20170281711A1
公开(公告)日：2017-10-05
申请号：US15456392
申请日：2017-03-10
Applicant: Acceleron Pharma Inc. , Adimab, LLC
Inventor： Ravindra KUMAR , Jonathan Belk , Asya Grinberg , Dianne Sako , Roselyne Castonguay
Abstract: This disclosure provides ActRII-binding proteins such as anti-ActRIIA and anti-ActRIIB antibodies, and compositions and methods for making the ActRII-binding proteins. In certain aspects the ActRII-binding proteins inhibit, or antagonize ActRII activity. In addition, the disclosure provides compositions and methods for diagnosing and treating diseases and conditions associated muscle wasting; a fibrotic condition; an inflammatory, cardiovascular, pulmonary, musculoskeletal, neurologic, ocular, skeletal, autoimmune, or metabolic disease or condition; wound healing; and cancer, and other ActRII-mediated diseases and conditions.
-
公开(公告)号：US20240374671A1
公开(公告)日：2024-11-14
申请号：US18739701
申请日：2024-06-11
Applicant: Acceleron Pharma Inc.
Inventor： Ravindra Kumar , Jonathan Belk , Asya Grinberg , Dianne Sako , Roselyne Castonguay
Abstract: This disclosure provides ActRII-binding proteins such as anti-ActRIIA and anti-ActRIIB antibodies, and compositions and methods for making the ActRII-binding proteins. In certain aspects the ActRII-binding proteins inhibit, or antagonize, ActRII activity. In addition, the disclosure provides compositions and methods for diagnosing and treating diseases and conditions associated muscle wasting; a fibrotic condition; an inflammatory, cardiovascular, pulmonary, musculoskeletal, neurologic, ocular, skeletal, autoimmune, or metabolic disease or condition; wound healing; and cancer, and other ActRII-mediated diseases and conditions.
-
公开(公告)号：US20210324089A1
公开(公告)日：2021-10-21
申请号：US17350608
申请日：2021-06-17
Applicant: Acceleron Pharma Inc.
Inventor： John Knopf , Jonathan Belk , Nathan J. Sharkey , Ravindra Kumar , Asya Grinberg , Dianne Sako , Roselyne Castonguay , Yossi Dagon
Abstract: This disclosure provides ALK7-binding proteins such as anti-ALK7 antibodies, and compositions and methods for making the ALK7-binding proteins. In certain embodiments the ALK7-binding proteins inhibit, or antagonize ALK7 activity. In addition, the disclosure provides compositions and methods for diagnosing and treating overweight, obesity, diabetes, overweight, obesity, type 2 diabetes, and their associated conditions; metabolic disorders, and other diseases or conditions that can be treated, prevented or ameliorated by targeting ALK7.
-
公开(公告)号：US20210308206A1
公开(公告)日：2021-10-07
申请号：US17231981
申请日：2021-04-15
Applicant: Acceleron Pharma Inc.
Inventor： Ravindra Kumar , Jonathan Belk , Asya Grinberg , Dianne Sako , Roselyne Castonguay
Abstract: This disclosure provides ActRII-binding proteins such as anti-ActRIIA and anti-ActRIIB antibodies, and compositions and methods for making the ActRII-binding proteins. In certain aspects the ActRII-binding proteins inhibit, or antagonize ActRII activity. In addition, the disclosure provides compositions and methods for diagnosing and treating diseases and conditions associated muscle wasting; a fibrotic condition; an inflammatory, cardiovascular, pulmonary, musculoskeletal, neurologic, ocular, skeletal, autoimmune, or metabolic disease or condition; wound healing; and cancer, and other ActRII-mediated diseases and conditions.
-
-
-
-
-
-
-
-
-
Search Results
15
records
(took 0.017 seconds)
